3Jonathan H.Overview of blood conservation[J].Transfusion,2003,50(6):65-75.
4Bohlius J,Weingart O,Trelle S,et al.Cancer-related anemia and recom-binant human erythropoietin—an updated overview[J].Nature ClincalPractice Oncology,2006,3(3):152-164.
5Serracino-Inglott F,Awad S,Barclay A,et al.The use of a cell saver dur-ing repair of ruptured abdominal aortic aneurysms increases early survival[J].Ann R Coll Surg Engl,2005,87(6):475.
6Dzik WH,Corwin H,Goodnough LT,et al.Patient safety and bloodtransfusion:new solutions[J].Transfusion Medicine Reviews,2003,3(17):169-180.
7Corwin HL.Blood conservation in the critically ill patient[J].Anesthe-siol Clin North America.2005,23(2):363-372.
8Cromheecke S,Lorsomradee S,Van der Linden PJ,et al.Moderate acuteisovolemic hemodilution alters myocardial functionin patients with coro-nary artery disease[J].Anesth Analg,2008,107(4):1145-1152.
9Carlessp A,Moxey A,O'conell D,et al.Autologous transfusion tech-niques:a systematic review of their efficacy[J].Transfus Med,2004,14(2):123-144.
10Ahmad M,Rees RC,Ali SA.Escape from immunotherapy:possiblemechanisms that influence tumor regression/progression[J].CancerImmunol Immunother,2004,53(10):844-854.
